MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/360/0.01/20.09.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/360/0.01/20.09.24 Share Price

DE000ME4N303

Delayed Börse Stuttgart 12:59:17 02/07/2024 BST
1.16 ^EUR	+2.65%

Current month	-4.24%
1 month	+17.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/360/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	01:34pm	BU
Vertex to Announce Second Quarter 2024 Financial Results on August 1	07-01	BU
Verve Therapeutics, Inc. Announces Board Appointments	06-28	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT

More news

Quotes 5-day view

Date	Price	Change
02/07/24	1.16	+2.65%
01/07/24	1.13	-4.24%
28/06/24	1.18	+0.85%
27/06/24	1.17	0.00%
26/06/24	1.17	+0.86%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 12:59 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME4N30
ISIN	DE000ME4N303
Date issued	05/12/2023
Strike	360 $
Maturity	20/09/2024 (80 Days)
Parity	100 : 1
Emission price	0.44 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.27 €
Lowest since issue	0.4 €
Delta	0.87x
Omega	3.290
Premium	2.91x
Gearing	3.77x
Moneyness	1.309
Difference Strike	-111.2 $
Difference Strike %	-30.90%
Spread	0.01 €
Spread %	0.85%
Theoretical value	1.165
Implied Volatility	60.11 %
Total Loss Probability	19.56 %
Intrinsic value	1.037
Present value	0.1280
Break even	484.98 €
Theta	-0.01x
Vega	0x
Rho	0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

471.2 USD

Average target price

468.3 USD

Spread / Average Target

-0.63%

Consensus